MARKET

NTLA

NTLA

Intellia Therape
NASDAQ
16.03
+0.53
+3.42%
Pre Market: 15.70 -0.33 -2.06% 05:55 06/26 EDT
OPEN
15.62
PREV CLOSE
15.50
HIGH
16.26
LOW
15.58
VOLUME
3.10K
TURNOVER
--
52 WEEK HIGH
28.25
52 WEEK LOW
7.95
MARKET CAP
2.24B
P/E (TTM)
-4.5363
1D
5D
1M
3M
1Y
5Y
1D
Short interest heatmap: Here are the most heavily bet-against stocks
Seeking Alpha · 1d ago
As AbbVie eyes Apogee, these biotech stocks earn the highest Quant ratings
Seeking Alpha · 3d ago
Weekly Report: what happened at NTLA last week (0615-0619)?
Weekly Report · 4d ago
Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera
NASDAQ · 06/19 09:09
Intellia Therapeutics rises 12.9%
TipRanks · 06/17 16:06
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday
Benzinga · 06/17 14:11
Intellia Therapeutics rises 10.7%
TipRanks · 06/17 14:07
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Intellia Therapeutics (NTLA)
TipRanks · 06/16 09:32
More
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.

Webull offers Intellia Therapeutics Inc stock information, including NASDAQ: NTLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NTLA stock methods without spending real money on the virtual paper trading platform.